Articles: function.
-
ILD Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Sarcoidosis is a multisystem inflammatory disorder.Usually the diagnosis is sugestted by clinical symptoms and chest radiography, but further investigations are required. Sometimes the diagnosis is difficult, especially when patient presents with interstitial lung syndrome. ⋯ Case of sarcoidosis in patient with asthma-like symptoms, treated for a long period of time only for obstructive symptoms due to sarcoidosis lesions of the bronchi or obstructive syndrome associated to sarcoidosis.Reference #1: 1DISCLOSURE: The following authors have nothing to disclose: Raluca Geamalinga, Ionela Belaconi, Stefan Dumitrache-Rujinski, Claudia Toma, Miron Alexandru BogdanNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: In the last 30 years only a few countries have gone to pursue the development of a registry in Pulmonary Artery Hypertension in which the specific characteristics of their population is evaluated and classified. In Puerto Rico this kind of information has never been collected and analyzed. Data was obtained from the only available specialized clinic in pulmonary hypertension in the island to characterize the demographics and clinical course of the Puerto Rican population and to compare individuals according to classification subgroup, treatment strategies and outcome. ⋯ The following authors have nothing to disclose: Alvaro Aranda, Elba Martin, Ricardo Fernandez, Jose Nieves, Jose Basora, Pedro TorrellasNo Product/Research Disclosure Information.
-
Critical care medicine · Mar 2014
Monitoring of Spinal Cord Perfusion Pressure in Acute Spinal Cord Injury: Initial Findings of the Injured Spinal Cord Pressure Evaluation Study.
To develop a technique for continuously monitoring intraspinal pressure at the injury site (intraspinal pressure) after traumatic spinal cord injury. ⋯ Our findings provide proof-of-principle that subdural intraspinal pressure at the injury site can be measured safely after traumatic spinal cord injury.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We retrospectively reviewed the complications occurred in the immediate postoperatory (IPO) of lung transplantation (LTx). ⋯ Jordi Rello: Grant monies (from sources other than industry): Study financed partly with Spanish Government Grant FIS PI11/01122 The following authors have nothing to disclose: Jordi Riera, Berta Caralt, Salvador Augustin, Joan Ramon Masclans, Merce Canela, Antonio RomanNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), versus placebo and tiotropium. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Grant monies (from industry related sources): Boehringer Ingelheim, Novartis, and Sunovion, Consultant fee, speaker bureau, advisory committee, etc.: GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.